Ocugen Inc (OCGN)
$1.7
Insights on Ocugen Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 315.6%
Performance
- $1.68$1.78$1.70
1.47%
Downside
Day's Volatility :5.9%
Upside
4.49%
- $0.35$2.08$1.70
79.71%
Downside
52 Weeks Volatility :83.41%
Upside
18.27%
Returns
| Period | Ocugen Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 93.18% | -1.0% | 0.0% |
6 Months | 331.47% | 9.6% | 0.0% |
1 Year | 261.32% | 11.0% | 0.0% |
3 Years | -80.5% | 18.5% | -22.6% |
Highlights
Market Capitalization | 445.2M |
Book Value | $0.12 |
Earnings Per Share (EPS) | -0.23 |
Wall Street Target Price | 6.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -1204.73% |
Return On Assets TTM | -50.4% |
Return On Equity TTM | -108.76% |
Revenue TTM | 6.6M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 128.9% |
Gross Profit TTM | -49.8M |
EBITDA | -59.0M |
Diluted Eps TTM | -0.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.22 |
EPS Estimate Next Year | -0.29 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | -0.07 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 292.35%
Technicals Summary
Sell
Neutral
Buy
Ocugen Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Ocugen Inc | 4.29% | 331.47% | 261.32% | -80.5% | 848.66% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Ocugen Inc | NA | NA | NA | -0.22 | -1.09 | -0.5 | NA | 0.12 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Ocugen Inc | Buy | $445.2M | 848.66% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
Vanguard Group Inc
4.66%BlackRock Inc
1.48%Geode Capital Management, LLC
1.25%Millennium Management LLC
0.75%Susquehanna International Group, LLP
0.47%Two Sigma Investments LLC
0.40%
Company Information
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Organization | Ocugen Inc |
Employees | 65 |
CEO | Dr. Shankar Musunuri M.B.A., Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.70
-1.73%
Keyarch Acquisition Corp
$1.70
-1.73%
Connexa Sports Technologies Inc
$1.70
-1.73%
Us Value Etf
$1.70
-1.73%
First Wave Biopharma Inc
$1.70
-1.73%
Global X Msci Next Emerging
$1.70
-1.73%
Fat Projects Acquisition Corp
$1.70
-1.73%
Goal Acquisitions Corp
$1.70
-1.73%
Capital Link Global Fintech
$1.70
-1.73%